These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3144546)

  • 21. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.
    Rolston KV; Nguyen HT; Ho DH; LeBlanc B; Bodey GP
    Antimicrob Agents Chemother; 1992 Apr; 36(4):879-82. PubMed ID: 1503453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
    Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y
    J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro evaluation of Ro 23-6240, a new fluorinated 4-quinolone.
    Stobberingh EE; Houben AW; van Boven CP
    Chemotherapy; 1987; 33(3):197-203. PubMed ID: 3109817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
    Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
    Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():35-41. PubMed ID: 3144547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial activity of norfloxacin and other agents against ocular pathogens.
    Shungu DL; Tutlane VK; Weinberg E; Gadebusch HH
    Chemotherapy; 1985; 31(2):112-8. PubMed ID: 3157551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of pefloxacin compared with five other quinolones on nalidixic acid-resistant proteae species.
    Piccolomini R; Cellini L; Allocati N; Di Girolamo A; Selan L; Scazzocchio F
    Chemioterapia; 1988 Oct; 7(5):287-91. PubMed ID: 3224396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of norfloxacin against urinary tract pathogens.
    Haase D; Urias B; Harding G; Ronald A
    Eur J Clin Microbiol; 1983 Jun; 2(3):235-41. PubMed ID: 6224679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R; Andrews JM; Danks G
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
    Qadri SM; Ueno Y; Ayub A
    Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative "in vitro" activity of ciprofloxacin (Bay o9867) and other antimicrobial agents against urinary bacterial isolates.
    Piccolomini R; Ravagnan G
    Chemioterapia; 1986 Aug; 5(4):249-56. PubMed ID: 3769047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli.
    Zhanel GG; Karlowsky JA; Schwartz B; Jensen SB; Hoban DJ
    Chemotherapy; 1998; 44(6):391-6. PubMed ID: 9755298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.